Compass Therapeutics Stock Price, News & Analysis

Compass Therapeutics, Inc. (Nasdaq: CMPX) is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company’s scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth, with the goal of generating effective anti-tumor responses across a range of solid and hematologic malignancies. Compass Therapeutics was founded in 2014 and is headquartered in Boston, Massachusetts.

According to the company’s public disclosures, Compass has built a pipeline of novel product candidates designed to target multiple critical biological pathways required for an effective anti-tumor response. These pathways include modulation of the microvasculature via angiogenesis-targeted agents, induction of a potent immune response via activators on effector cells in the tumor microenvironment, and alleviation of immunosuppressive mechanisms used by tumors to evade immune surveillance. The company plans to advance its product candidates through clinical development as standalone therapies and in combination with proprietary pipeline antibodies based on supportive clinical and nonclinical data.

Core scientific focus and therapeutic approach

Compass Therapeutics describes its scientific strategy as centered on the interplay between angiogenesis (the formation of new blood vessels), immune regulation, and tumor biology. By targeting angiogenesis, the company aims to affect the tumor microvasculature, which can influence how tumors grow and respond to therapy. At the same time, its programs seek to activate effector cells in the tumor microenvironment and reduce immunosuppressive mechanisms that allow tumors to evade immune surveillance.

This multi-pathway approach is reflected in the company’s antibody-based product candidates, many of which are bispecific antibodies designed to engage more than one target. Publicly described programs include antibodies directed at DLL4 and VEGF-A, PD-1 and PD-L1, PD-1 and VEGF-A, and CD137. These targets are associated with angiogenesis, immune checkpoint regulation, and immune cell co-stimulation, which together are intended to support a coordinated anti-tumor immune response.

Key clinical and preclinical product candidates

Compass Therapeutics reports a pipeline that includes several named product candidates:

• Tovecimig (DLL4 x VEGF-A bispecific antibody) – A bispecific antibody that targets DLL4 and VEGF-A. Tovecimig is being evaluated in the Phase 2/3 randomized COMPANION-002 study in patients with advanced biliary tract cancer (BTC). The company has stated that this study met its primary endpoint of overall response rate when tovecimig plus paclitaxel was compared with paclitaxel alone, and that analyses of key secondary endpoints, including progression-free survival (PFS) and overall survival (OS), are planned based on pre-specified events. Tovecimig has also been studied as monotherapy in patients with advanced, metastatic colorectal cancer (CRC) treated in later-line settings, where Compass has reported monotherapy activity and has highlighted outcomes in patients with DLL4-positive tumors.
• CTX-8371 (PD-1 x PD-L1 bispecific antibody) – A bispecific antibody targeting PD-1 and PD-L1. In a Phase 1 dose-escalation study, Compass has reported responses in patients with both solid tumors and hematologic malignancies in the post-checkpoint inhibitor setting. Public updates describe deep and durable responses in indications such as non-small cell lung cancer (NSCLC) and triple negative breast cancer (TNBC), as well as responses in Hodgkin Lymphoma (HL). The company has opened cohort expansions for CTX-8371 in TNBC and NSCLC and is evaluating potential accelerated pathways for HL in the post-checkpoint inhibitor setting.
• CTX-10726 (PD-1 x VEGF-A bispecific antibody) – A bispecific, tetravalent antibody that simultaneously targets VEGF-A and PD-1. Compass reports that CTX-10726 is being developed for metastatic or locally advanced tumor types where checkpoint and angiogenesis signals are present. In preclinical studies described by the company, CTX-10726 demonstrated high-affinity binding to VEGF-A and PD-1, blocked VEGF-A/VEGFR2 and PD-1/PD-L1 interactions in a dose-dependent manner, and showed anti-tumor activity in multiple in vivo models. The company has indicated that CTX-10726 is undergoing IND-enabling studies and that it plans a Phase 1 dose-escalation study.
• CTX-471 (CD137 agonist antibody) – A CD137 (4-1BB) agonist antibody that Compass states binds a unique epitope of the co-stimulatory molecule 4-1BB with an optimized affinity. The company has indicated that it expects to initiate a Phase 2 trial of CTX-471 in patients with tumors expressing NCAM (CD56).

In addition to these named programs, earlier descriptions of the company’s pipeline reference candidates such as CTX-009 and a VEGF-IO bispecific, reflecting a broader effort to explore multiple antibody formats and targets within its core scientific framework.

Oncology focus and disease areas

Compass Therapeutics characterizes itself as an oncology-focused biopharmaceutical company. Across its clinical and preclinical programs, the company’s disclosures reference work in advanced biliary tract cancer, colorectal cancer, non-small cell lung cancer, triple negative breast cancer, and Hodgkin Lymphoma, among other DLL4-positive and PD-(L)1-positive tumor types. The company’s public statements emphasize development in settings where patients often have limited approved therapeutic options, including later-line treatment of certain cancers and post-checkpoint inhibitor settings.

By designing antibodies that engage angiogenesis pathways and immune checkpoints simultaneously, or that provide immune co-stimulation, Compass aims to address tumors that may not respond adequately to single-pathway therapies. The company’s pipeline is described as being suitable for evaluation both as monotherapy and in combination with other agents, including standard-of-care regimens and other proprietary antibodies.

Capital markets and listing information

Compass Therapeutics, Inc. is listed on the Nasdaq Capital Market under the trading symbol CMPX. The company has filed shelf registration statements and conducted underwritten public offerings of common stock and pre-funded warrants, as described in its Form 8-K filings. In these filings, Compass has stated that it intends to use offering proceeds to fund research and clinical development of its product candidates, initial preparations for commercial readiness, and general corporate purposes. The company has also disclosed expectations regarding its cash and marketable securities and anticipated cash runway, while noting that these expectations are based on assumptions that may change.

Regulatory and reporting profile

As a U.S. public company, Compass Therapeutics files periodic and current reports with the Securities and Exchange Commission (SEC), including Forms 10-K, 10-Q, and 8-K. Recent 8-K filings have covered financial results, corporate presentations, and material financing agreements. These filings provide additional detail on the company’s operating expenses, research and development activities, general and administrative costs, and balance sheet items such as cash, marketable securities, and lease obligations.

Position within biopharmaceutical development

Within the broader biopharmaceutical landscape, Compass Therapeutics presents itself as a company focused on antibody engineering and immuno-oncology. Its emphasis on bispecific antibodies targeting combinations such as DLL4/VEGF-A, PD-1/PD-L1, and PD-1/VEGF-A, alongside a CD137 agonist program, reflects a strategy of engaging multiple mechanisms relevant to tumor growth, angiogenesis, and immune modulation. Publicly available information highlights the company’s intention to use clinical and nonclinical data to guide the advancement of these candidates, including decisions about monotherapy versus combination approaches and selection of tumor types for further study.

FAQs about Compass Therapeutics, Inc. (CMPX)

• What does Compass Therapeutics, Inc. do?
  Compass Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company that develops proprietary antibody-based therapeutics to treat multiple human diseases. Its scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth, and it is advancing a pipeline of product candidates targeting key biological pathways involved in anti-tumor responses.
• What is the main scientific focus of Compass Therapeutics?
  The company’s scientific focus is on how angiogenesis, immune regulation, and tumor growth interact. Compass designs antibody-based therapeutics to modulate the tumor microvasculature, activate effector immune cells, and reduce immunosuppressive mechanisms, with the aim of enhancing anti-tumor immunity.
• Which product candidates has Compass Therapeutics publicly described?
  Compass has publicly described several product candidates, including tovecimig (a DLL4 x VEGF-A bispecific antibody), CTX-8371 (a PD-1 x PD-L1 bispecific antibody), CTX-10726 (a PD-1 x VEGF-A bispecific tetravalent antibody), and CTX-471 (a CD137 agonist antibody). Earlier descriptions also reference CTX-009 and a VEGF-IO bispecific.
• In which disease areas is Compass Therapeutics conducting clinical work?
  Public disclosures indicate that Compass is conducting or planning clinical studies in oncology indications such as advanced biliary tract cancer, colorectal cancer, non-small cell lung cancer, triple negative breast cancer, and Hodgkin Lymphoma, among other DLL4-positive and PD-(L)1-positive tumor types.
• What is tovecimig and how is it being studied?
  Tovecimig is described by Compass as a DLL4 x VEGF-A bispecific antibody. It is being evaluated in the COMPANION-002 Phase 2/3 randomized study in patients with advanced biliary tract cancer, where tovecimig plus paclitaxel has been reported to improve overall response rate compared with paclitaxel alone. Tovecimig has also been studied as monotherapy in advanced, metastatic colorectal cancer in later-line settings.
• What is CTX-8371 and what data has Compass reported?
  CTX-8371 is a PD-1 x PD-L1 bispecific antibody. In a Phase 1 dose-escalation study, Compass has reported responses in patients with solid tumors and hematologic malignancies in the post-checkpoint inhibitor setting, including deep and durable responses in non-small cell lung cancer and triple negative breast cancer, and responses in Hodgkin Lymphoma. Cohort expansions in TNBC and NSCLC are open for enrollment.
• What is CTX-10726 and what has been shown in preclinical studies?
  CTX-10726 is a bispecific, tetravalent antibody targeting VEGF-A and PD-1. Compass reports that in preclinical studies, CTX-10726 showed high-affinity binding to VEGF-A and PD-1, blocked VEGF-A/VEGFR2 and PD-1/PD-L1 interactions in a dose-dependent manner, and demonstrated anti-tumor activity in multiple in vivo models. It is being advanced through IND-enabling studies, with plans for a Phase 1 dose-escalation trial.
• What is CTX-471?
  CTX-471 is described as a CD137 agonist antibody that binds a unique epitope of the co-stimulatory molecule 4-1BB with an optimized affinity. Compass has indicated that it expects to initiate a Phase 2 trial of CTX-471 in patients with tumors expressing NCAM (CD56).
• Where is Compass Therapeutics headquartered and when was it founded?
  Compass Therapeutics, Inc. was founded in 2014 and is headquartered in Boston, Massachusetts, according to the company’s public statements.
• On which exchange does CMPX trade and what type of company is it?
  Compass Therapeutics, Inc.’s common stock trades on the Nasdaq Capital Market under the ticker symbol CMPX. It is described in SEC filings and press releases as a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics.